News
Hims & Hers, the high-flying online health company that rapidly grew from a buzzy startup selling Viagra to a ...
StockStory.org on MSN1d
Hims & Hers Health (HIMS) Stock Is Up, What You Need To KnowWhat Happened? Shares of telehealth company Hims & Hers Health (NYSE:HIMS) jumped 4.1% in the morning session after the ...
From a receding hairline to thinning crown and balding, hair loss can be a difficult personal experience for many men as they ...
Novo Nordisk will lose its patent protection on its branded semaglutide drugs Ozempic and Wegovy in Canada after not paying a maintenance fee in 2019.
U.S. telehealth platform looks to take advantage of Ozempic patent expiring in January, while four manufacturers filed for ...
Hims & Hers Health reports 111% Q1 2025 revenue growth to $586M, driven by personalized treatments & strong margins. Read why ...
Explore more
The move follows a dramatic breakup in June between Hims & Hers and Danish drug maker Novo Nordisk, which makes the brand name weight loss drug Wegovy. Novo Nordisk accused the Hims & Hers of ...
Analysts said the deal with Novo was likely giving Hims “‘credibility’ or increased consumer traffic,” adding that the ...
9don MSN
Hims & Hers Health (HIMS -3.91%) is a telehealth company that offers personalized solutions for its customers. And demand has ...
Hims & Hers stands out for personalized, compounded medications and consistent margin expansion but faces rising risks tied ...
Hims & Hers announced plans to expand its weight loss program to Canada in 2026 in connection with the availability of generic semaglutide anywhere in the world.
Hims & Hers Health plans to expand into Canada, timing it with the new availability of the generic weight loss medication on the market for the first time.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results